



American Society of Clinical Oncology

Abstract Notices

The Editor of the *2016 ASCO Annual Meeting Proceedings* has authorized correction of the following errors:

510, 519, 520, 611, TPS613, TPS617, TPS1101, TPS1105, 1511, 8541, 9084, 11500, TPS11621

Notice of Correction: Conflict of interest information for José Baselga, MD, PhD, has been updated to reflect previously undisclosed relationships. The corrected disclosures of potential conflicts of interest provided by the author are available with the online abstracts on JCO.org and ASCO.org.

LBA1

The abstract body published in the *2016 Annual Meeting Proceedings Part II* reflects an earlier version of the abstract. The authors discovered an error in the eligibility criteria of the patient population enrolled: "A total of 1,918 women with T1-3, N1-2 breast cancer were enrolled" has been changed to "A total of 1,918 women with early stage breast cancer were enrolled."

LBA509

Notice of Retraction: "Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results."

ASCO's Confidentiality Policy requires that abstracts be considered confidential and embargoed from the time of submission until the findings have been publicly released in conjunction with the ASCO Annual Meeting. Abstract LBA509, published in the *2016 ASCO Annual Meeting Proceedings Part II*, violated this policy and was retracted from publication and presentation at the 2016 ASCO Annual Meeting.

All errors have been corrected in the online versions of the abstracts on JCO.org and ASCO.org. This notice is updated on a rolling basis, as needed.